Topics

BioMotiv Company Profile

05:05 EDT 16th September 2019 | BioPortfolio

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of drug development programs.


News Articles [14 Associated News Articles listed on BioPortfolio]

BMS partners with BioMotiv to form new companies

Biopharmaceutical company Bristol-Myers Squibb (BMS) has partnered with drug development accelerator BioMotiv to form and fund new companies for the...Read More... The post BMS partners with BioMotiv ...

BMS becomes limited partner in BioMotiv, holds options to acquire investments

Bristol-Myers Squibb Co. agreed to become a limited partner in BioMotiv LLC. Together they will establish start-ups, which BMS might eventually buy.

Rutgers, BioMotiv launch cancer immunotherapy company startup

TamRx, a cancer immunotherapy firm, was launched jointly by BioMotiv and Rutgers University on Thursday to advance its experi -More- 

BMS, BioMotiv enter limited partnership for drug development

Bristol-Myers Squibb has entered a limited partnership with BioMotiv, a drug development accelerator, to support research at  -More- 

Bristol-Myers Squibb and BioMotiv Partner to Form and Fund New Companies to Develop Novel Therapeutics

CLEVELAND & NEW YORK–(BUSINESS WIRE)–BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Br...

BioMotiv, Rutgers launch TamRx

Bristol-Myers Squibb invests in drug development accelerator BioMotiv

The pharmaceutical giant seeks to accelerate scientific discoveries into breakthrough therapies for patients living with severe diseases

BioMotiv and Bristol-Myers Squibb Form Strategic Partnership

BioMotiv, a mission-driven drug development accelerator that advances breakthrough discoveries from research institutions into therapeutics, and Bristol-Myers Squibb Company (NYSE: BMY) today announc...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

BioMotiv

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million initiative for advancing medicine centered at Univers...

Koutif Therapeutics

About BioMotiv

More Information about "BioMotiv" on BioPortfolio

We have published hundreds of BioMotiv news stories on BioPortfolio along with dozens of BioMotiv Clinical Trials and PubMed Articles about BioMotiv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMotiv Companies in our database. You can also find out about relevant BioMotiv Drugs and Medications on this site too.

Quick Search

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record